Cart (0 Items)
Your cart is currently empty.
View ProductsIt looks like you are visiting from outside the EU. Switch to the US version to see local pricing in USD and local shipping.
Switch to US ($)
Whether for therapeutics, diagnostics, or research, ProteoGenix delivers custom antibody production services tailored to your specific application. With our exclusive performance guarantee, antibodies are validated directly in your laboratory, ensuring you only move forward with antibodies that truly work in your system.
Tool
Answer a few questions and find the technology that best fits your target, application and timeline.
Over 20 years of expertise in custom antibody production.
Depending on your project, we guarantee either a defined number of binders or functional performance in your target application (validated in your lab).
Antibodies are tested both in-house by ProteoGenix and directly in your laboratory, ensuring reliable real-world performance in your experimental conditions.
Human, mouse, humanized mouse, rat, rabbit, dog, cat, camelids, and all major antibody formats including IgG, Fab, scFv, and VHH, optimized for diverse applications.
You retain complete IP rights and full ownership over all generated antibodies generated within your project.
Our diversified technologies enable alternative and complementary strategies when standard approaches fail.
From antigen design to stable cell line development, we support the entire workflow to reduce multi-vendor friction.
A leading antibody development company
ProteoGenix is a specialized provider of custom antibody production services supporting biotechnology companies, pharmaceutical developers, and academic research laboratories worldwide. Our integrated platform combines antibody discovery, sequencing, engineering, and recombinant production to accelerate antibody development from concept to validated candidate.
AIxplore® de novo antibody generation
A dedicated PhD expert oversees your entire custom antibody development project, ensuring continuity and precision at every stage. From antigen design to custom cell line development, our services operate in full synergy, enabling us to manage all aspects of your project seamlessly. With more than 6000 antibodies developed, our expertise allows us to deliver solutions suited to any application. To keep you in full control, we have integrated multiple Go/No-Go checkpoints throughout the process, allowing informed decisions at every step.
With our extensive range of technologies, we design a tailored strategy fully adapted to your scientific needs. Thanks to the combination of our advanced platforms, we can address any type of antigen, whether peptide, protein, small molecule, membrane protein or even toxic or poorly immunogenic targets. Techniques that do not require immunization, such as phage display or de novo antibody generation, also allow us to develop antibodies when classical approaches are not suitable.
Discover how we successfully generated a custom antibody against a low-immunogenic peptide using a combination of our advanced techniques.
N Tirado et al., CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia. J Hematol Oncol 18, 69 (2025).
https://doi.org/10.1186/s13045-025-01715-0
R López-Aladid et al., Epitope mapping of SARS-CoV-2 Spike protein using naturally-acquired immune responses to develop monoclonal antibodies. Sci Rep 15, 16269 (2025).
https://doi.org/10.1038/s41598-025-00555-9
M Pitaro et al., Development of a recombinant human IgG1 monoclonal antibody against the TRBV5-1 segment of the T cell receptor for the treatment of mature T cell neoplasms. Front Immunol 15, 1520103 (2024).
https://doi.org/10.3389/fimmu.2024.1520103
H Sihto et al., Phosphodiesterase 3 A expression in gastrointestinal stromal tumors. Virchows Arch 487, 983–991 (2025).
https://doi.org/10.1007/s00428-025-04150-1
Trusted by Research, Biotech, and Academic Teams Worldwide